Compare BIO-TECHNE Corp (TECH) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs T Rowe Price Group Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while T Rowe Price Group Inc trades at $113.73 (market cap $24.27B). The key difference: T Rowe Price Group Inc is far larger — about 2.2× BIO-TECHNE Corp's market cap, and T Rowe Price Group Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| TECH | TROW | |
|---|---|---|
Market Cap | $11.24B | $24.27B |
Sector | Health | Financials |
52-Week High | $72.29 | $121.68 |
52-Week Low | $43.31 | $86.19 |
Enterprise Value | $11.32B | $21.46B |
Dividend Yield | 0.44% | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
T. Rowe Price (TROW) trades at $114.02, up 0.35% today, with a neutral technical outlook and mixed analyst sentiment. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51, driven by record assets under management and higher advisory fees. The stock trades at a P/E of 11.45, below industry averages, indicating potential undervaluation. Dividend payments remain stable at $1.30 per share, supporting income investors.
Outlook is cautiously optimistic given strong profitability metrics like a 29.26% net income margin and 20.1% ROE, but risks include expense pressures and net outflows. Analyst consensus price target is $112.17, slightly below current price, with 63% hold ratings suggesting limited near-term upside. Investors should weigh solid fundamentals against competitive headwinds in the asset management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
